Cyprotex and Peakdale collaborate on ADME prediction technology

UK companies Cyprotex and Peakdale Molecular are collaborating in the development of tools to help improve the design of new pharmaceutical compounds.

In the agreement, Cyprotex will use its Cloe Screen technology to evaluate the ADME properties of up to 8,500 compounds developed and synthesised by Peakdale. The companies will use the data to develop predictive models that will be used to enhance the design of novel compounds.

Cloe Screen, Cyprotex's cost-efficient, high throughput screening system, will generate a large and highly consistent data set on Peakdale's compounds which will form a crucial basis for predicting the properties of compounds which have yet to be synthesised. This capability will help to enhance the ADME profile of compound libraries and provide a better starting point from which to discover potential new drugs.

'In order to develop better drugs faster, the industry needs to start with compounds that have the best potential to succeed as drugs,' said Cyprotex ceo Robert Morrisson Atwater. 'Without the ability to predict effectively how compounds will behave in the body, pharmaceutical companies have to perform time- and cost-consuming iterations of design and synthesis.

'Cloe Screen will ensure that we have a good basis from which to build predictive models to enable our pharmaceutical and biotechnology partners to improve the efficiency of their drug discovery.'